The global ESRD market includes a broad linkage of elements that work towards identification, treatment, and management in the face of end-stage renal disease. Diagnosis and surveillance consist of a plethora of diagnostic measurements including blood, and urine tests to evaluate the progression stages of kidney disease.
There are several treatment options inside the marketplace for kidney disease, which include dialysis (hemodialysis and peritoneal dialysis) and kidney transplantation, offering an extended life to patients. Continuous studies and improvement endeavors are targeted at investigating the causes of kidney ailment and enhancing treatment options via strategies like regenerative medication.
The Global End-Stage Renal Disease (ESRD) Market is experiencing substantial expansion due to an increasing prevalence of chronic kidney disease (CKD) and an aging population. With increasing incidents of end stage renal disease around the globe, dialysis treatments, kidney transplantation procedures, and related medical devices are in demand and creating opportunities for innovative technologies within this space.
Advances in dialysis technology such as home dialysis systems have transformed patient care. There has been an emphasis on personalized treatments options to achieve improved outcomes; gene and stem cell therapies could play a pivotal role in providing long-term solutions to ESRD patients in the near future.
ESRD market growth may also benefit from opportunities in developing regions, where awareness of kidney disease and access to treatments are expanding rapidly. Furthermore, governments and
healthcare organizations are investing heavily in healthcare infrastructure improvements which is expected to drive market expansion further. As demand for better healthcare solutions surges further still, significant investments into research, new therapies, and treatment delivery should propel this market further still.
Hemodialysis remains the preferred dialysis option, accounting for 70-75% of dialysis market while peritoneal dialysis accounts for 25-35%. Kidney transplantation remains highly in demand with over 100,000 Americans waiting on transplant lists nationwide; additionally innovative therapies like gene and stem cell research should have an exponentially positive effect in shaping treatment landscape.
The Global End-Stage Renal Disease (ESRD) Market presents significant opportunities through advancements in home dialysis technologies, gene therapy, and personalized medicine. With increasing prevalence and demand for treatments like dialysis and kidney transplants, expanding access in developing regions and growing adoption of telehealth for remote monitoring offer substantial growth potential in patient care and treatment outcomes.
Key Takeaways
- Dialysis dominates the global end-stage renal disease market in the context of the treatment plan as it holds 79.1% of the market share in 2023.
- Blood tests dominate this segment based on diagnosis in the global end-stage renal disease market as they hold the highest market share in 2023.
- Hospitals and clinics dominate this segment with the end-user segment as they hold 52.9% of market value in 2023.
- Asia Pacific dominates the global end-stage renal disease market as it holds 38.4% of the market share in 2023.
- Following Asia Pacific North America and Europe show the highest growth potential in the global end-stage renal disease market in 2023.
Use Cases
- Personalized Dialysis Treatment Plans: Advancements in home dialysis systems and remote monitoring enable customized treatment plans for ESRD patients, improving comfort and long-term outcomes.
- Kidney Transplantation & Organ Donation: As ESRD cases rise, the demand for kidney transplants grows. Innovations in organ preservation, along with gene and stem cell research, may enhance transplant success and reduce wait times.
- Regenerative Medicine for Kidney Disease: Stem cell and gene therapies are emerging as potential solutions for regenerating kidney tissue, offering alternatives to dialysis and transplants for long-term ESRD management.
- Point-of-Care Diagnostics: Advanced blood, urine tests, and imaging technologies facilitate early ESRD detection, enabling timely interventions and reducing the need for invasive treatments.
- Telehealth & Remote Dialysis Monitoring: Telehealth platforms and remote monitoring systems allow healthcare providers to track ESRD patients at home, reducing hospital visits while ensuring continuous care and support.
Market Dynamic
In the dynamic landscape of the global end-stage renal disease (ESRD) marketplace, various factors contribute to the growth of this marketplace. The increasing global occurrence of persistent kidney ailment (CKD) propels the demand for ESRD treatment as patients progress to later stages. The growing aging populace, mainly susceptible to kidney-related situations, plays a critical role in the growing occurrence of end-stage renal sickness.
Ongoing technological advancements and innovations in dialysis machines and faraway tracking, enhance the efficiency and accessibility of ESRD treatment. A remarkable shift towards home-based dialysis and far-flung patient tracking displays converting care transport choices stimulated through affected person choices, fee-effectiveness, and improvements in
telehealth. This market has embraced personalized medicine, driven via genetic profiling and precision medication, which in addition shapes remedy approaches. Healthcare reform, coverage, and regulatory changes affect entry to treatment, pricing, and the use of generation.
Research Scope and Analysis
By Treatment
Dialysis dominates the global end-stage renal disease market in the context of the treatment plan as it holds 79.1% of the market share in 2023 and is projected to show subsequent growth in the forecasted period of 2023 to 2032. Dialysis, encompassing both hemodialysis and peritoneal dialysis, is a predominant treatment modality for end-stage renal disease (ESRD) due to its widespread accessibility, immediate symptom relief, established clinical efficacy, and flexible treatment settings.
It is characterized by routine monitoring, the ability to manage complications effectively, and comprehensive patient education and support programs. A dialysis is a cost-effective option compared to kidney transplantation, making it more accessible to a larger population of ESRD patients.
It provides immediate availability, serving as a crucial bridge to transplantation for those awaiting a suitable organ.
While kidney transplantation is the preferred long-term treatment, factors such as organ availability and patient suitability contribute to the ongoing prevalence of dialysis as a vital and widely utilized therapeutic approach for ESRD patients. The choice between dialysis and transplantation involves
medical suitability, patient preferences, and logistical challenges, highlighting the importance of a personalized approach to treatment decisions.
By Diagnosis
Blood tests dominate this segment based on diagnosis in the global end-stage renal disease market as they hold the highest market share in 2023 and are expected to show such growth rate in the upcoming period as well. Blood tests dominate the diagnostic approach for end-stage renal disease due to their capacity to offer important statistics about renal function and ordinary fitness.
Essential markers inclusive of serum creatinine and blood urea nitrogen (BUN) aid in assessing renal characteristics and gauging the severity of impairment. These assessments also estimate the glomerular filtration fee (GFR), presenting insights into the general kidney feature and ailment stage. Blood tests additionally examine electrolyte and mineral stability, hit upon anemia through a complete blood count (CBC), and check acid-base stability.
Specific biomarkers assist in discovering kidney damage and screening disease progression, while blood tests additionally aid in evaluating metabolic issues and identifying underlying causes of a kidney ailment. Routine tracking of drug degrees is facilitated through blood tests, ensuring effective management of signs and complications in patients with ESRD. While blood exams are significant to ESRD prognosis, a complete evaluation may also contain other diagnostic modalities relying on the scientific context and particular patient care desires.
By End-User
Hospitals and clinics dominate this segment with the end-user segment as they hold 52.9% of market value in 2023 and are expected to show the following growth in the forthcoming period as well. The dominance of hospitals and clinics in the end-user segment of the end-stage renal disease (ESRD) marketplace may be attributed to their potential to offer complete care, a superior clinical system, and a multidisciplinary approach.
These healthcare settings offer a range of clinical services and specialties, facilitating coordination among diverse healthcare experts concerned with ESRD treatment. The complexity of ESRD care, such as surgical interventions like kidney transplantation, aligns with the state-of-the-art infrastructure and era located in hospitals.
Additionally, hospitals are geared up to deal with inpatient and in-depth care offerings, emergencies, and critical situations associated with ESRD. They play a crucial role in schooling and teaching healthcare specialists focusing on renal care, ensuring a professional staff. While there is a developing fashion toward domestic-based totally and outpatient care, hospitals continue to be vital for dealing with complicated cases, surgical tactics, and emergencies related to stop-level renal ailment.
The End Stage Renal Disease Market Report is segmented on the basis of the following:
By Treatment
- Dialysis
- Hemodialysis
- Peritoneal Dialysis
- Transplant
By Diagnosis
- Blood Test
- Urine Test
- Imaging Test
- Others
By End-User
- Hospitals & Clinics
- Dialysis Centers
- Others
Regional Analysis
Asia Pacific dominates the global end-stage renal disease market as it holds 38.4% of the market share in 2023 and is predicted to show subsequent growth in the upcoming period of 2023 to 2032. A growing prevalence of continual kidney ailment (CKD) in this area, fueled by the developing older populations, way of life adjustments, and a surge in non-communicable diseases, contributes to the excessive occurrence of end-stage renal disease market.
With a huge and growing populace, such as an increasingly aged demographic, the call for renal care inside the Asia-Pacific location is notably substantial. Urbanization and evolving life have led to better costs of situations like diabetes and high blood pressure, primary members to chronic kidney disease and end-stage renal disorder. Improvements in healthcare get entry to, governmental tasks supporting renal care, monetary increase fostering an increasing middle class with improved healthcare access, and a focus on domestic-based dialysis and telehealth offerings in addition to contributing to the area's dominance within the worldwide end-level renal disease marketplace.
By Region
North America
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- ANZ
- ASEAN
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Egypt
- Rest of MEA
Competitive Landscape
The global end-stage renal disease (ESRD) market is formed with the aid of the presence of several key gamers including Fresenius Medical Care, DaVita Inc., Baxter International Inc., Nipro Corporation, and Fresenius-received NxStage Medical, Inc. These most important groups play pivotal roles in imparting dialysis services and products to customers, positively contributing to the progress of the aggressive landscape of the worldwide give-up-level renal disease marketplace.
There are various factors that impact the competition of a few of the important agencies in this marketplace which encompass a focal point on technological innovation, with corporations investing in superior dialysis machines and home-based remedy alternatives. Global growth and a strong presence in rising markets are important for competitive success.
Some of the prominent players in the Global End Stage Renal Disease Market are:
- Abbott
- Amgen Inc.
- AstraZeneca
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Limited
- Pfizer Inc.
- GlaxoSmithKline plc
- Keryx Biopharmaceuticals Inc.
- Kissei Pharmaceutical Co. Limited
- Novartis
- Other Key Players
Recent Developments
- In September 2023, Cytecare in Bengaluru unveiled a cutting-edge dialysis center dedicated to treating kidney-related diseases which signifies Cytecare's commitment to advancing a comprehensive approach to healthcare services.
- In May 2023, Pathalys Pharma, a private biopharmaceutical company in its late stage, successfully enrolled its first patient ahead of schedule in a pivotal phase program designed for hemodialysis.
- In January 2023, Boehringer Ingelheim and Eli Lilly and Company jointly announced that the U.S. Food and Drug Administration (FDA) had granted approval for a supplemental new drug application for Jardiance tablets.
- In May 2023, DaVita Inc. and Medtronic plc joined forces to create an independent medical device company focused on kidney and renal care where it prioritized advanced therapies for kidney failure, the partnership aims to enhance accessibility by providing home-based products for various dialysis treatments.
- In April 2022, Fresenius Medical Care received approval from the United States FDA for the Versi PD Cycler System, a cutting-edge portable automated peritoneal dialysis system now authorized for use in North America.
- In March 2022, The Health Minister inaugurated a Hemodialysis unit at New Souillac in Mauritius on World Kidney Day. The unit, equipped with 22 machines, aims to decentralize kidney disease treatment, providing expanded access for approximately 150 patients.
Report Details
| Report Characteristics |
| Market Size (2023) |
USD 119.4 Bn |
| Forecast Value (2032) |
USD 398.7 Bn |
| CAGR (2023-2032) |
14.2% |
| Historical Data |
2018 – 2023 |
| Forecast Data |
2024 – 2033 |
| Base Year |
2023 |
| Estimate Year |
2024 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc. |
| Segments Covered |
By Dosage (Capsule, Tablet, and Oral Solution), By
Type (Generic, and Branded), By Application
(Epilepsy, Neuropathic Pain, Restless Legs Syndrome,
and Others), By Distribution Channel (Hospital
Pharmacy, Retail Pharmacy, and Online Pharmacy) |
| Regional Coverage |
North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
|
| Prominent Players |
Abbott, Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Hoffmann-La Roche Limited, Pfizer Inc., GlaxoSmithKline plc, Keryx Biopharmaceuticals Inc., Kissei Pharmaceutical Co. Limited, Novartis, and Other Key Players
|
| Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively. |